Islet Sciences Inc Aktie

Aktien

Verzögert OTC Markets Andere Börsenplätze 15:53:58 26.07.2017			% 5 Tage	% 1. Jan.
0.0127 ^USD	+5.75%		+5.75%	-76.93%

Dauer

Zeitraum

Stil

Islet Sciences, Inc. Publishes Data Supporting Remogliflozin Etabonate as a Potential Treatment for NAFLD and NASH	04.05.15
Islet Sciences, Inc. Presented at 50th International Liver Conference	23.04.15
Islet Sciences, Inc. COO to Present at Metabolic Leaders Forum	24.03.15
Islet Sciences, Inc. COO to Present at EASL: Remogliflozin Etabonate as Novel Treatment for Non-alcoholic Steatohepatitis (NASH)	09.03.15
Islet Sciences, Inc. Confirms Issuance of U.S. Patent for Using SGLT2 Inhibitors to Treat NASH/NAFLD	05.03.15

1 Tag

+5.75%

Sektor

	% 1. Jan.	Kap.
IQVIA HOLDINGS INC.	+1.51%	42.75 Mrd.
LONZA GROUP AG	+49.22%	41.61 Mrd.
MODERNA, INC.	+8.57%	41.34 Mrd.
CELLTRION, INC.	-12.36%	26.59 Mrd.
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49 Mrd.
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12 Mrd.
MEDPACE HOLDINGS, INC.	+29.17%	12.24 Mrd.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76 Mrd.
UNITED THERAPEUTICS CORPORATION	+6.35%	11 Mrd.